By Ben Butkus

Catalyst Pharmaceutical Partners said yesterday that it has exclusively licensed from Northwestern University the commercial rights to GABA aminotransferase inhibitors and derivatives of the anti-epileptic drug vigabatrin.

Catalyst, based in Coral Gables, Fla., said the compounds may have applications for a broad range of neurological diseases, including addiction and epilepsy, and has identified and begun to develop an undisclosed, lead oral compound.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.